332 related articles for article (PubMed ID: 15987450)
21. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
[TBL] [Abstract][Full Text] [Related]
22. A polymorphism in CYP17 and endometrial cancer risk.
Haiman CA; Hankinson SE; Colditz GA; Hunter DJ; De Vivo I
Cancer Res; 2001 May; 61(10):3955-60. PubMed ID: 11358812
[TBL] [Abstract][Full Text] [Related]
23. CYP17 gene polymorphism in relation to breast cancer risk: a case-control study.
Einarsdóttir K; Rylander-Rudqvist T; Humphreys K; Ahlberg S; Jonasdottir G; Weiderpass E; Chia KS; Ingelman-Sundberg M; Persson I; Liu J; Hall P; Wedrén S
Breast Cancer Res; 2005; 7(6):R890-6. PubMed ID: 16280037
[TBL] [Abstract][Full Text] [Related]
24. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India.
Dwivedi S; Agrawal S; Singh S; Madeshiya AK; Singh D; Mahdi AA; Chandra A
Asian Pac J Cancer Prev; 2015; 16(13):5557-63. PubMed ID: 26225710
[TBL] [Abstract][Full Text] [Related]
25. CYP17 gene polymorphism and its association in north Indian prostate cancer patients.
Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P
Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382
[TBL] [Abstract][Full Text] [Related]
26. The CYP17 MspA1 Polymorphism and the Gender Dysphoria.
Fernández R; Cortés-Cortés J; Esteva I; Gómez-Gil E; Almaraz MC; Lema E; Rumbo T; Haro-Mora JJ; Roda E; Guillamón A; Pásaro E
J Sex Med; 2015 Jun; 12(6):1329-33. PubMed ID: 25929975
[TBL] [Abstract][Full Text] [Related]
27. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Spurdle AB; Hopper JL; Dite GS; Chen X; Cui J; McCredie MR; Giles GG; Southey MC; Venter DJ; Easton DF; Chenevix-Trench G
J Natl Cancer Inst; 2000 Oct; 92(20):1674-81. PubMed ID: 11036113
[TBL] [Abstract][Full Text] [Related]
28. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women.
McCann SE; Moysich KB; Freudenheim JL; Ambrosone CB; Shields PG
J Nutr; 2002 Oct; 132(10):3036-41. PubMed ID: 12368392
[TBL] [Abstract][Full Text] [Related]
29. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore.
Wu AH; Seow A; Arakawa K; Van Den Berg D; Lee HP; Yu MC
Int J Cancer; 2003 Apr; 104(4):450-7. PubMed ID: 12584742
[TBL] [Abstract][Full Text] [Related]
30. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
31. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
32. Genetic variation in the CYP17 gene and recurrent spontaneous abortions.
Litridis I; Kapnoulas N; Natisvili T; Agiannitopoulos K; Peraki O; Ntostis P; Pantos K; Lamnissou K
Arch Gynecol Obstet; 2011 Feb; 283(2):289-93. PubMed ID: 20069306
[TBL] [Abstract][Full Text] [Related]
33. Association of a CYP17 gene polymorphism with development of breast cancer in India.
Surekha D; Sailaja K; Rao DN; Padma T; Raghunadharao D; Vishnupriya S
Asian Pac J Cancer Prev; 2010; 11(6):1653-7. PubMed ID: 21338212
[TBL] [Abstract][Full Text] [Related]
34. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany.
Vesovic Z; Herkommer K; Vogel W; Paiss T; Maier C
Anticancer Res; 2005; 25(2B):1303-7. PubMed ID: 15865082
[TBL] [Abstract][Full Text] [Related]
35. [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women].
Hu MB; Xie W; Xiong B; Han DF; Li Y; Feng MH; Zhou YF
Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr; 27(4):351-5. PubMed ID: 16875543
[TBL] [Abstract][Full Text] [Related]
36. Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.
Onland-Moret NC; van Gils CH; Roest M; Grobbee DE; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):815-20. PubMed ID: 15824149
[TBL] [Abstract][Full Text] [Related]
37. Association between CYP17 gene polymorphism and risk of breast cancer in young women.
Bergman-Jungeström M; Gentile M; Lundin AC; Wingren S
Int J Cancer; 1999 Aug; 84(4):350-3. PubMed ID: 10404084
[TBL] [Abstract][Full Text] [Related]
38. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.
Antognelli C; Del Buono C; Ludovini V; Gori S; Talesa VN; Crinò L; Barberini F; Rulli A
BMC Cancer; 2009 Apr; 9():115. PubMed ID: 19379515
[TBL] [Abstract][Full Text] [Related]
39. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):120-6. PubMed ID: 12582021
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy.
Feigelson HS; McKean-Cowdin R; Pike MC; Coetzee GA; Kolonel LN; Nomura AM; Le Marchand L; Henderson BE
Cancer Res; 1999 Aug; 59(16):3908-10. PubMed ID: 10463580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
